Acadia Healthcare Company, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on March 11 and March 12, 2013. Acadia Healthcare Company, Inc. (the "Company") executed significant capital market transactions involving the issuance of new senior notes, the redemption of existing senior notes, and amendments to its credit facility.
Key Financial Metrics and Transactions
- New Debt Issuance: Sold $150,000,000 aggregate principal amount of 6.125% Senior Notes due 2021.
- Debt Redemption: Redeemed $52,500,000 of 12.875% Senior Notes due 2018.
- Redemption Cost: The 2018 Notes were redeemed at 112.875% of principal plus accrued interest.
- Interest Rate: New 2021 Notes bear interest at 6.125% per annum, payable semi-annually.
- Proceeds Usage: Net proceeds from the new offering are designated for general corporate purposes, including potential acquisitions.
Material Changes and Agreements
The filing details three primary material changes:
- Entry into Material Definitive Agreement (New Notes): The Company entered into a Purchase Agreement on March 7, 2013, and completed the sale of the 2021 Notes on March 12, 2013. The Notes are senior unsecured obligations, fully and unconditionally guaranteed by subsidiary guarantors. They include covenants limiting dividends, additional debt, asset sales, and mergers, though certain covenants may be suspended if the Notes achieve investment-grade ratings.
- Registration Rights Agreement: The Company agreed to file a registration statement for an exchange offer within 360 days of closing. Failure to meet registration obligations will result in an interest rate penalty increasing by 0.25% per annum, up to a maximum of 1.0% additional interest.
- Credit Facility Amendment: On March 11, 2013, the Company amended its Amended and Restated Credit Agreement. The amendment modified the definition of Consolidated EBITDA to allow add-backs for fees related to the redemption of the 2018 Notes and permitted testing indebtedness net of cash or cash equivalents.
Outlook, Risks, and Contingencies
The Company intends to use the net proceeds from the new debt offering for general corporate purposes, explicitly mentioning acquisitions as a potential use. The new indenture contains customary events of default and restrictive covenants regarding financial flexibility (dividends, debt, asset transfers). A specific contingency exists regarding the Registration Rights Agreement; if the Company fails to file required registration statements within specified timeframes, the cost of debt will increase.
Investor Verification Checklist
- Verify the exact net proceeds received from the $150 million offering after deducting underwriting fees and expenses.
- Confirm the total cash outflow for the redemption of the 2018 Notes, including the 12.875% premium and accrued interest.
- Review the specific terms of the "First Amendment" to the Credit Agreement to understand the new EBITDA calculation and debt testing mechanics.
- Monitor the Company's progress on filing the exchange offer registration statement to avoid the 0.25% to 1.0% interest rate penalty.
- Assess the impact of the new 6.125% interest rate versus the redeemed 12.875% rate on future interest expense.